

## Abstract

R. Formento-Cavaier<sup>1</sup>, I. Zahi<sup>1</sup>, M. Mariani<sup>1</sup>

<sup>1</sup>Advanced Accelerator Applications, a Novartis company, 5 via Ribes, Colletterto Giacosa, 10010, Italy

AAA's expertise in developing, producing and commercializing Nuclear Medicine theragnostics agents stems from more than 15-year legacy as a leader in radiopharmaceuticals, including both PET and SPECT imaging agents therapy agents. Our main product on therapy of GEP-NET is a ready-to-inject solution of <sup>177</sup>Lu-Dotatate (Lutathera) with marketing registration in both USA and EU.

In the framework of AAA's R&D activities, the early stage research project "MEDICIS-produced radioisotope beams for medicine" (MEDICIS PROMED, a Marie Skłodowska-Curie Innovative Training Network of the Horizon 2020 EU program) has been actively supported. The aim of AAA participation was to investigate the use of electromagnetic isotopes mass separation (EMIS) technology applied to the production of radionuclides. This project had brought new knowledge and competences into the company.

The throughput of this project was successful; therefore, AAA would appreciate to be part of a subsequent new project consortium within the HORIZON 2020 framework and contribute to the development of the technology around mass separation already started within MEDICIS-PROMED.